Marcello Arca

Pubblicazioni

Titolo Pubblicato in Anno
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study ATHEROSCLEROSIS PLUS 2021
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile ATHEROSCLEROSIS PLUS 2021
Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper JOURNAL OF CARDIOVASCULAR MEDICINE 2021
Dislipidemia: i nuovi target e importanza delle terapie di associazione GIORNALE ITALIANO DI CARDIOLOGIA 2021
Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES 2020
Hdl-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically-but not genetically driven non-alcoholic fatty liver disease (Nafld) BIOMEDICINES 2020
Evolocumab in pediatric heterozygous familial hypercholesterolemia NEW ENGLAND JOURNAL OF MEDICINE 2020
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy JOURNAL OF CLINICAL LIPIDOLOGY 2020
Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study JOURNAL OF INTERNAL MEDICINE 2020
Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort JOURNAL OF LIPID RESEARCH 2020
High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects DIABETES/METABOLISM RESEARCH AND REVIEWS 2020
Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review ADVANCES IN THERAPY 2020
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries CARDIOVASCULAR THERAPEUTICS 2020
ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS 2020
Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk italian population: The TG-REAL Retrospective Cohort Analysis JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE 2020
Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts GIORNALE ITALIANO DI CARDIOLOGIA 2020
Lipoprotein (a): a genetic marker for cardiovascular disease and target for emerging therapies JOURNAL OF CARDIOVASCULAR MEDICINE 2020
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials CURRENT ATHEROSCLEROSIS REPORTS 2020
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia EXPERT OPINION ON PHARMACOTHERAPY 2020
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry INTERNATIONAL JOURNAL OF CARDIOLOGY 2020

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma